Board of Directors
Suzanne Bruhn, Ph.D. has served as a director of Novelion since October 2017. Dr. Bruhn currently serves as the President and Chief Executive Officer of Tiaki Therapeutics, Inc., a private biotechnology company. Prior to Tiaki, she served as the President and Chief Executive Officer of Proclara Biosciences, Inc., a clinical-stage biotechnology company, from April 2017 to September 2018. Prior to Proclara, from May 2012 to November 2015, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc. She also served as a member of the board of directors of Raptor Pharmaceuticals Corp., a publicly-traded biopharmaceutical company, from 2011 until it was acquired by Horizon Pharma plc in 2016. Previously, Dr. Bruhn served in a number of roles of increasing responsibility at Shire, a biopharmaceutical company, from 1998 until 2012, most recently as Senior Vice President, Strategic Planning and Program Management. Dr. Bruhn currently also serves on the board of directors of Aeglea BioTherapeutics, Inc., a publicly-traded biotechnology company focused on the treatment of rare genetic diseases and cancer, and Pliant Therapeutics, a private biotechnology company. She received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology.
Michael Price serves Novelion as Executive Vice President and Chief Financial Officer and, since his appointment in October 2019, as a member of the Board of Directors. Prior to joining Novelion in December of 2017, he served as Vice President and Chief Financial Officer for Noven Pharmaceuticals, Inc. (“Noven”), a NASDAQ-listed company until its acquisition by Hisamitsu Pharmaceutical Company. Noven is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. In his role at Noven, Mr. Price was directly involved with the development and execution of strategy that scaled the Company's commercial organization and significantly increased revenues. Prior to Noven, he was Vice President, Chief Financial Officer, Treasurer, Secretary and a member of the Board of Directors for Bentley Pharmaceuticals, a New York Stock Exchange-listed company until its acquisition by Teva Pharmaceutical Industries. Mr. Price is a certified public accountant. He holds a bachelor of science degree in business administration (accounting) from Auburn University and a master of business administration degree from Florida State University.
Stephen Sabba, M.D. has served as a director of Novelion since 2012. Currently, Dr. Sabba is also a Partner and Health Care Portfolio Manager at Knott Partners, LP, an investment fund, and a director of Ligand Pharmaceuticals Inc., a public biotechnology company, positions he has held since 2006 and 2008, respectively. Previously, from 2001 to 2006, he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago based hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. degree with honors at Cornell University.